# US 11,298,425 B2 · Delivery of a chemotherapy agent across the blood-brain barrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,425 B2
- Document ID: US11298425B2
- Status: Granted
- Kind: B2
- Application number: 16/892,215
- Filed: 2020-06-03
- Published: 2020-09-17
- Granted: 2022-04-12
- Earliest claimed: 2018-01-19
- Assignees: Rowlesbiomed, LLC
- Applicants: Rowlesbiomed, LLC
- Inventors: Heidi Rowles
- Web page: https://patentgrep.com/patent/US11298425B2

## CPC

- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A therapeutic method and composition which includes a cannabinoid chemically linked to a chemotherapy agent. The therapeutic composition is capable of crossing the blood-brain barrier, and delivery of the composition across the blood-brain barrier provides both chemotherapy for the treatment of brain cancer and alleviation of side effects caused by the chemotherapy agent. Once across the blood-brain barrier, the chemotherapy agent will be released to attack cancer cells, and the cannabinoid will be free to bind to cannabinoid receptors in the brain to alleviate side effects of chemotherapy such as nausea/vomiting, pain and decreased appetite.

## Claims

### Claim 1

A method of treating a patient suffering from cancer of the brain, the method comprising administering to the patient a therapeutically effective amount of a composition comprising a cannabinoid and a chemotherapy agent, wherein the cannabinoid and chemotherapy agent are chemically linked, wherein the composition is capable of crossing the blood-brain barrier to provide both chemotherapy for the treatment of brain cancer and alleviation of side effects caused by the chemotherapy agent, and wherein the cannabinoid is tetrahydrocannabivarin and the chemotherapy agent is Carmustine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chemical link between tetrahydrocannabivarin and Carmustine is cleavable after crossing the blood-brain barrier, thereby allowing tetrahydrocannabivarin to bind to cannabinoid receptors in the brain while also allowing Carmustine to attack cancer cells in the brain.

### Claim 3 (depends on 1)

The method of claim 1, wherein the side effect caused by the chemotherapy agent is nausea.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is formulated to be administered in the form of an inhaler.

### Claim 5 (depends on 1)

The method of claim 1, wherein the brain cancer is glioblastoma multiforme.